Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
Published By: Decision Resources
June 2009
R55-650
PDF E-mail From Publisher $2,250.00
Global Site License Fulfilled by Publisher $4,500.00
Description
Introduction
For decades, the efficacy of hormone replacement therapy (HRT) for some of menopause’s most
troublesome symptoms eliminated any incentive to develop new approaches to treatment. However,
data questioning the safety of estrogen-containing therapies have galvanized researchers and drug
developers to begin investigating new mechanisms to treat menopausal symptoms that can capitalize
on the newly realized need for safer treatment options, although these agents will still be challenged
by the efficacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied b • y substantial hormonal changes.
What are the symptoms of menopause? What are the causes of these symptoms? What are the
current treatment options? What are the benefits and drawbacks of these treatments?
- Data from the Women’s Health Initiative suggest that estrogen therapy is not suitable for all women.
What are the risks associated with hormone therapy? Do emerging agents offer safer or more
efficacious treatment approaches?
- With the final wave of baby boomers reaching menopausal age, the menopause treatment patient
population is on the rise. What were the sales of menopausal symptom treatments in 2008? How
well will emerging agents address the remaining needs in this market? How will emerging
agents fit into the treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen receptor
modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth’s Pristiq, Wyeth’s bazedoxifene/conjugated estrogens,
Depomed’s controlled-release gabapentin, Schering-Plough’s esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of emerging agents, the
future of HRT.
- Women’s Health Series: This report is part of Spectrum’s Women’s Health Series, which
focuses on areas of unmet need and the best marketing strategies to ensure adoption of a
new agent into the market for women’s reproductive health—a sector that exceeded $23
billion in 2007.
|
Table of Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Menopause
- Defi nition and Description
- Symptoms of Menopause
- Vasomotor Symptoms
- Osteoporosis
- Increased Cardiovascular Disease Risk
- Insomnia
- Depression
- Other Symptoms
- Current Treatments for Menopausal Symptoms
- Hormone Replacement Therapy
- Selective Estrogen Receptor Modulators
- Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors
- Gabapentin
- Other Treatments
- Emerging Treatments for Menopausal Symptoms
- Wyeth’s Pristiq
- Wyeth’s Bazedoxifene/Conjugated Estrogen Combination
- Depomed’s Gabapentin
- Schering-Plough’s Esmirtazapine
- Outlook for the Menopausal Symptom Market
- Tables
- 1. Common Brands of Hormone Replacement Therapy
- 2. Common Selective Serotonin Reuptake Inhibitors and Serotonin and Norepinephrine Reuptake Inhibitors
- 3. Emerging Agents for the Treatment of Menopausal Symptoms
- 4. Sales of Agents to Treat Menopausal Symptoms, 2008
- Figures
- 1. Endocrine Changes Associated with Menopause
- 2. Worldwide Sales of Hormone Replacement Therapy, 2003-2008
|
Order Form * Please reference product number R55-650 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
